{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:08:39Z","timestamp":1789002519041,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05417-y","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:26:25Z","timestamp":1782282385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic and clinical insights into the coexistence of multiple myeloma and diffuse large B cell lymphoma from a case report and systematic review with bioinformatics analysis"],"prefix":"10.1007","volume":"17","author":[{"given":"Alireza","family":"Zangooie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moein","family":"Piroozkhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobin","family":"Pirouzkhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Sardarkhani","family":"Eydgahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malihe","family":"Saberafsharian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Sanei-Far","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhosein","family":"Maharati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolghasem","family":"Allahyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"5417_CR1","unstructured":"Albagoush SA, Shumway C, Azevedo AM. Continuing education activity."},{"issue":"2","key":"5417_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3892\/ol.2014.2185","volume":"8","author":"S Zhou","year":"2014","unstructured":"Zhou S, Ma Y, Bi L, Shen Z, Yu K. Simultaneous occurrence of two B-cell malignancies: a case report. Oncol Lett. 2014;8(2):908\u201310.","journal-title":"Oncol Lett"},{"issue":"7","key":"5417_CR3","doi-asserted-by":"publisher","first-page":"e68041","DOI":"10.1371\/journal.pone.0068041","volume":"8","author":"HE Tzeng","year":"2013","unstructured":"Tzeng HE, Lin CL, Tsai CH, Tang CH, Hwang WL, Cheng YW, et al. Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: a Taiwan population-based study. PLoS ONE. 2013;8(7):e68041.","journal-title":"PLoS ONE"},{"issue":"1","key":"5417_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13256-023-03753-z","volume":"17","author":"A Allahyari","year":"2023","unstructured":"Allahyari A, Maharati A, Jafari-Nozad AM, Zangooie A. Prostate cancer, chronic myelogenous leukemia and multiple myeloma in a single patient: a case report and review of the literature. J Med Case Rep. 2023;17(1):35.","journal-title":"J Med Case Rep"},{"key":"5417_CR5","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"5417_CR6","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors. Joanna Briggs Institute Reviewer's Manual: The Joanna Briggs Institute; 2017."},{"key":"5417_CR7","unstructured":"Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017;2017."},{"issue":"9","key":"5417_CR8","first-page":"e44542","volume":"15","author":"T D'Ovidio","year":"2023","unstructured":"D\u2019Ovidio T, Ciccolini K, Kalac M, Osman K, Steinberg A. CD19-targeted chimeric antigen receptor T-cell therapy for concomitant diffuse large B-cell lymphoma and multiple myeloma. Cureus. 2023;15(9):e44542.","journal-title":"Cureus"},{"key":"5417_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jns.2017.11.005","volume":"384","author":"PG Eye","year":"2018","unstructured":"Eye PG, Wang B, Keung ES, Tagg NT. Anti-ZIC4 associated paraneoplastic cerebellar degeneration in a patient with both diffuse large B-cell lymphoma and incidental smoldering multiple myeloma. J Neurol Sci. 2018;384:36\u20137.","journal-title":"J Neurol Sci"},{"issue":"1","key":"5417_CR10","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1159\/000548795","volume":"18","author":"P Ganachari","year":"2025","unstructured":"Ganachari P, Dev Vashishta G, Ramani VK, Naik R. A rare presentation of multiple myeloma as a second primary cancer sequential to non-hodgkin lymphoma: case report. Case Rep Oncol. 2025;18(1):1562\u201374.","journal-title":"Case Rep Oncol"},{"issue":"1","key":"5417_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s12308-025-00667-1","volume":"18","author":"AC Gibbs","year":"2025","unstructured":"Gibbs AC, Batchala PP, Gottlieb CE, Balle BO, Obiorah IE, Foster LH, et al. Staging FDG PET\/CT prediction of bone marrow involvement by diffuse large B-cell lymphoma leading to delayed recognition of multiple myeloma. J Hematop. 2025;18(1):49.","journal-title":"J Hematop"},{"key":"5417_CR12","doi-asserted-by":"crossref","unstructured":"Juma F, Alangari S, AlMutairi O, AlMutairi T, Binkhamis K. Weissella confusa infection in an immunocompromised patient: A case report. IDCases. 2026;43.","DOI":"10.1016\/j.idcr.2026.e02491"},{"issue":"16","key":"5417_CR13","doi-asserted-by":"publisher","first-page":"e19739","DOI":"10.1097\/MD.0000000000019739","volume":"99","author":"T Li","year":"2020","unstructured":"Li T, Tan J, Chen L, Kuang D, Mao X, Lou Y, et al. Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy. Medicine (Baltimore). 2020;99(16):e19739.","journal-title":"Medicine (Baltimore)"},{"key":"5417_CR14","first-page":"102355","volume":"47","author":"SK Luketich","year":"2023","unstructured":"Luketich SK, Zekan DS, Prisneac I, Howell DM, El Naili R, Zaslau S. EBV-positive diffuse large B-cell lymphoma presenting as symptomatic masses in the bladder trigone and unilateral kidney. Urol Case Rep. 2023;47:102355.","journal-title":"Urol Case Rep"},{"key":"5417_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jdcr.2023.09.015","volume":"41","author":"AB Shahin","year":"2023","unstructured":"Shahin AB, Greene A, Reeder CB, Costello CM, Pittelkow MR, DiCaudo DJ. Paraneoplastic morphea with prominent mucin deposition. JAAD Case Rep. 2023;41:110\u20132.","journal-title":"JAAD Case Rep"},{"issue":"4","key":"5417_CR16","first-page":"e70102","volume":"8","author":"G Ceparano","year":"2025","unstructured":"Ceparano G, Lorenzini D, Ponzoni M, Levati G, Epifania D, Marasco V. Tailored therapeutic approach in a patient with diffuse large B-cell lymphoma with meningeal infiltration, concurrent classic Hodgkin lymphoma, and Smoldering multiple myeloma: a case report. Cancer Rep. 2025;8(4):e70102.","journal-title":"Cancer Rep"},{"key":"5417_CR17","doi-asserted-by":"crossref","unstructured":"Li N, Liu X, Song Y, Luo S, Fang B. The synchronous presence of multiple myelomas and other primary malignant tumors: case series with literature review. Cancer Manag Res. 2020:2829\u201338.","DOI":"10.2147\/CMAR.S238288"},{"issue":"3","key":"5417_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.4103\/0377-4929.188110","volume":"59","author":"S Mitra","year":"2016","unstructured":"Mitra S, Mukherjee S, Mehta J, Bhattacharyya M, Chakraborty H. Concomitant occurrence of multiple myeloma with diffuse large B-cell lymphoma. Indian J Pathol Microbiol. 2016;59(3):427\u20138.","journal-title":"Indian J Pathol Microbiol"},{"issue":"8","key":"5417_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.vgie.2023.05.003","volume":"8","author":"KM Pawlak","year":"2023","unstructured":"Pawlak KM, Khalaf K, M\u00f6nkem\u00fcller K, Kurek K. Systemic multiple myeloma and colonic abnormalities. VideoGIE. 2023;8(8):328\u20139.","journal-title":"VideoGIE"},{"issue":"6","key":"5417_CR20","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00277-020-03975-x","volume":"99","author":"K Yoshihara","year":"2020","unstructured":"Yoshihara K, Yoshihara S, Matsuda I, Imado T, Matsuo S, Okada M, et al. Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion. Ann Hematol. 2020;99(6):1405\u20137.","journal-title":"Ann Hematol"},{"key":"5417_CR21","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.2147\/CMAR.S238288","volume":"12","author":"N Li","year":"2020","unstructured":"Li N, Liu X, Song Y, Luo S, Fang B. The synchronous presence of multiple myelomas and other primary malignant tumors: case series with literature review. Cancer Manag Res. 2020;12:2829\u201338.","journal-title":"Cancer Manag Res"},{"issue":"16","key":"5417_CR22","doi-asserted-by":"publisher","first-page":"e19739","DOI":"10.1097\/MD.0000000000019739","volume":"99","author":"T Li","year":"2020","unstructured":"Li T, Tan J, Chen L, Kuang D, Mao X, Lou Y, et al. Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy. Medicine. 2020;99(16):e19739.","journal-title":"Medicine"},{"key":"5417_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/IJGM.S171387","volume":"11","author":"M Saito","year":"2018","unstructured":"Saito M, Miyashita K, Miura Y, Ogasawara R, Kanaya M, Izumiyama K, et al. Coexistence of primary colorectal follicular lymphoma and multiple myeloma: a case report. Int J General Med. 2018;11:363\u20137.","journal-title":"Int J General Med"},{"issue":"2","key":"5417_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/cmrp.cmrp_150_23","volume":"14","author":"P Moule","year":"2024","unstructured":"Moule P, Langer S, Kotwal J, Gupta D, Agarwal C, Gupta N. Synchronous dual haematological malignancies\u2014Multiple myeloma and low-grade B-cell lymphoma\u2014a case report and review of the literature. Curr Med Res Pract. 2024;14(2):81\u20134.","journal-title":"Curr Med Res Pract"},{"issue":"3","key":"5417_CR25","first-page":"183","volume":"75","author":"E Grau","year":"1986","unstructured":"Grau E, Soler J, Puig J, Brunet S, Pujol-Moix N, Rodriguez J, et al. Coincident multiple myeloma and non-Hodgkin\u2019s lymphoma with 2 serum monoclonal immunoglobulins. Acta Haematol. 1986;75(3):183\u20135.","journal-title":"Acta Haematol"},{"issue":"6","key":"5417_CR26","first-page":"206","volume":"4","author":"A Danandehmehr","year":"2020","unstructured":"Danandehmehr A, Mashhadi Z. A case report on concurrent presentation of non-Hodgkin lymphoma and multiple myeloma. Eur J Med Case Rep. 2020;4(6):206\u20139.","journal-title":"Eur J Med Case Rep"},{"issue":"2","key":"5417_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3904\/kjim.1994.9.2.113","volume":"9","author":"GC Lee","year":"1994","unstructured":"Lee GC, Hong JS, Lee KH, Kim SB, Kim SW, Suh CW, et al. A case of coincident multiple myeloma and non-Hodgkin\u2019s lymphoma. Korean J Intern Med. 1994;9(2):113\u20135.","journal-title":"Korean J Intern Med"},{"key":"5417_CR28","doi-asserted-by":"publisher","first-page":"S536","DOI":"10.1016\/j.htct.2024.09.900","volume":"46","author":"DPM Almeida","year":"2024","unstructured":"Almeida DPM, Costa ES, Romano S, Land MGP. Occurrence of sequential multiple myeloma following b-cell Non-Hodgkin lymphoma: a case report. Hematol Transfusion Cell Ther. 2024;46:S536.","journal-title":"Hematol Transfusion Cell Ther"},{"issue":"5","key":"5417_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"1","key":"5417_CR30","doi-asserted-by":"publisher","first-page":"013","DOI":"10.17352\/ahcrr.000008","volume":"2","author":"Z Mozaheb","year":"2017","unstructured":"Mozaheb Z. Multiple Myeloma with scleroderma and second malignancy: a case report. Archives Hematol Case Rep Rev. 2017;2(1):013\u20135.","journal-title":"Archives Hematol Case Rep Rev"},{"issue":"36","key":"5417_CR31","doi-asserted-by":"publisher","first-page":"13520","DOI":"10.1073\/pnas.0804295105","volume":"105","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright GW, Emre NT, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci. 2008;105(36):13520\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"5417_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.14740\/wjon2611","volume":"16","author":"H Elwaheidi","year":"2025","unstructured":"Elwaheidi H, Hamad A, Salameh F, Elkordy F, FathAlrahman R, Hanbali A. IgM Myeloma: a comprehensive overview and practical approach to chemotherapeutic management. World J Oncol. 2025;16(5):427\u201338.","journal-title":"World J Oncol"},{"issue":"12","key":"5417_CR33","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"2","key":"5417_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.26796","volume":"98","author":"MA Gertz","year":"2023","unstructured":"Gertz MA. Waldenstr\u00f6m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023;98(2):348\u201358.","journal-title":"Am J Hematol"},{"key":"5417_CR35","doi-asserted-by":"crossref","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, et al. NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 1.2025: Featured Updates to the NCCN Guidelines\u00ae. J Natl Compreh Cancer Netw. 2025;23(5):132\u201340.","DOI":"10.6004\/jnccn.2025.0023"},{"key":"5417_CR36","doi-asserted-by":"crossref","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, et al. Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compreh Cancer Netw. 2024;22(1D).","DOI":"10.6004\/jnccn.2024.0001"},{"issue":"4","key":"5417_CR37","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamainternmed.2024.8124","volume":"185","author":"Y Liu","year":"2025","unstructured":"Liu Y, Parks AL. Diagnosis and management of monoclonal gammopathy of undetermined significance: a review. JAMA Intern Med. 2025;185(4):450\u20136.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"5417_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41408-022-00614-8","volume":"12","author":"LH Jakobsen","year":"2022","unstructured":"Jakobsen LH, \u00d8vlisen AK, Severinsen MT, B\u00e6ch J, Kragholm KH, Glimelius I, et al. Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark. Blood Cancer J. 2022;12(1):16.","journal-title":"Blood Cancer J"},{"issue":"4","key":"5417_CR39","first-page":"e57368","volume":"16","author":"SU Hassan","year":"2024","unstructured":"Hassan SU, Hussain S, Fakhar M, Ahmad A, Durrani F. Frequency of complete remission with R-CHOP therapy in patients with diffuse large B cell lymphoma. Cureus. 2024;16(4):e57368.","journal-title":"Cureus"},{"issue":"19","key":"5417_CR40","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782\u201391.","journal-title":"N Engl J Med"},{"issue":"1","key":"5417_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1182\/blood.2024026588","volume":"146","author":"C Chakraborty","year":"2025","unstructured":"Chakraborty C, Talluri S, Binder M, Morelli E, Mayoral JE, Derebail S, et al. Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma. Blood. 2025;146(1):104\u201314.","journal-title":"Blood"},{"key":"5417_CR42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.leukres.2018.07.025","volume":"72","author":"A Agnarelli","year":"2018","unstructured":"Agnarelli A, Chevassut T, Mancini EJ. IRF4 in multiple myeloma-Biology, disease and therapeutic target. Leuk Res. 2018;72:52\u20138.","journal-title":"Leuk Res"},{"issue":"7201","key":"5417_CR43","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer AL, Emre NT, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454(7201):226\u201331.","journal-title":"Nature"},{"issue":"49","key":"5417_CR44","doi-asserted-by":"publisher","first-page":"85392","DOI":"10.18632\/oncotarget.19907","volume":"8","author":"H Bai","year":"2017","unstructured":"Bai H, Wu S, Wang R, Xu J, Chen L. Bone marrow IRF4 level in multiple myeloma: an indicator of peripheral blood Th17 and disease. Oncotarget. 2017;8(49):85392\u2013400.","journal-title":"Oncotarget"},{"key":"5417_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.humpath.2022.10.011","volume":"131","author":"HE Berg","year":"2023","unstructured":"Berg HE, Peterson JF, Lee HE, McPhail ED. Large B-cell lymphoma with IRF4 gene rearrangements: differences in clinicopathologic, immunophenotypic and cytogenetic features between pediatric and adult patients. Hum Pathol. 2023;131:108\u201315.","journal-title":"Hum Pathol"},{"issue":"4","key":"5417_CR46","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s10238-022-00968-0","volume":"23","author":"R Maffei","year":"2023","unstructured":"Maffei R, Fiorcari S, Atene CG, Martinelli S, Mesini N, Pilato F, et al. The dynamic functions of IRF4 in B cell malignancies. Clin Exp Med. 2023;23(4):1171\u201380.","journal-title":"Clin Exp Med"},{"issue":"7","key":"5417_CR47","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/his.14885","volume":"82","author":"EA Hesius","year":"2023","unstructured":"Hesius EA, van Laar L, Oosterveld M, van Spriel AB, Scheijen B, Leeuwis JW, et al. Reclassification of diffuse large B cell lymphoma to large B cell lymphoma with IRF4 rearrangement in an adult population. Histopathology. 2023;82(7):1013\u201320.","journal-title":"Histopathology"},{"issue":"3","key":"5417_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ccr.2007.08.012","volume":"12","author":"IS Lossos","year":"2007","unstructured":"Lossos IS. The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF-4 downregulates BCL6 expression. Cancer Cell. 2007;12(3):189\u201391.","journal-title":"Cancer Cell"},{"issue":"10","key":"5417_CR49","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1038\/s41375-020-0919-5","volume":"34","author":"C Bali\u00f1as-Gavira","year":"2020","unstructured":"Bali\u00f1as-Gavira C, Rodr\u00edguez MI, Andrades A, Cuadros M, \u00c1lvarez-P\u00e9rez JC, \u00c1lvarez-Prado \u00c1F, et al. Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL. Leukemia. 2020;34(10):2722\u201335.","journal-title":"Leukemia"},{"issue":"12","key":"5417_CR50","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.4161\/cc.29213","volume":"13","author":"Q Liu","year":"2014","unstructured":"Liu Q, Zhou H, Langdon WY, Zhang J. E3 ubiquitin ligase Cbl-b in innate and adaptive immunity. Cell Cycle. 2014;13(12):1875\u201384.","journal-title":"Cell Cycle"},{"key":"5417_CR51","doi-asserted-by":"publisher","first-page":"1432545","DOI":"10.3389\/fphar.2024.1432545","volume":"15","author":"J Ren","year":"2024","unstructured":"Ren J, Lv L, Tao X, Zhai X, Chen X, Yu H, et al. The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies. Front Pharmacol. 2024;15:1432545.","journal-title":"Front Pharmacol"},{"issue":"1","key":"5417_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-022-00610-y","volume":"12","author":"M Martello","year":"2022","unstructured":"Martello M, Poletti A, Borsi E, Solli V, Dozza L, Barbato S, et al. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma. Blood Cancer J. 2022;12(1):15.","journal-title":"Blood Cancer J"},{"key":"5417_CR53","doi-asserted-by":"crossref","unstructured":"Flynt E, Bisht K, Sridharan V, Ortiz M, Towfic F, Thakurta A. Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma. Cells. 2020;9(2).","DOI":"10.3390\/cells9020287"},{"key":"5417_CR54","doi-asserted-by":"publisher","first-page":"1550207","DOI":"10.3389\/fonc.2025.1550207","volume":"15","author":"Y Jin","year":"2025","unstructured":"Jin Y, Wang Y, Wang L, Zhang H, Ren B, Zheng J, et al. TP53 mutation and immunohistochemical p53 expression characteristics in diffuse large B\u2013cell lymphoma. Front Oncol. 2025;15:1550207.","journal-title":"Front Oncol"},{"issue":"1","key":"5417_CR55","doi-asserted-by":"publisher","first-page":"1928365","DOI":"10.1080\/2162402X.2021.1928365","volume":"10","author":"H You","year":"2021","unstructured":"You H, Xu-Monette ZY, Wei L, Nunns H, Nagy ML, Bhagat G, et al. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. Oncoimmunology. 2021;10(1):1928365.","journal-title":"Oncoimmunology"},{"issue":"19","key":"5417_CR56","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120(19):3986\u201396.","journal-title":"Blood"},{"issue":"2","key":"5417_CR57","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7150\/thno.28374","volume":"9","author":"V Vikova","year":"2019","unstructured":"Vikova V, Jourdan M, Robert N, Requirand G, Boireau S, Bruyer A, et al. Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance. Theranostics. 2019;9(2):540\u201353.","journal-title":"Theranostics"},{"issue":"10","key":"5417_CR58","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.7150\/ijbs.93349","volume":"20","author":"QX Liu","year":"2024","unstructured":"Liu QX, Zhu Y, Yi HM, Shen YG, Wang L, Cheng S, et al. KMT2D mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC\/TGF-\u03b21 axis. Int J Biol Sci. 2024;20(10):3972\u201385.","journal-title":"Int J Biol Sci"},{"issue":"10","key":"5417_CR59","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/nm.3940","volume":"21","author":"J Zhang","year":"2015","unstructured":"Zhang J, Dominguez-Sola D, Hussein S, Lee JE, Holmes AB, Bansal M, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21(10):1190\u20138.","journal-title":"Nat Med"},{"issue":"12","key":"5417_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-020-00389-w","volume":"10","author":"TJ Bakhshi","year":"2020","unstructured":"Bakhshi TJ, Georgel PT. Genetic and epigenetic determinants of diffuse large B-cell lymphoma. Blood Cancer J. 2020;10(12):123.","journal-title":"Blood Cancer J"},{"issue":"1","key":"5417_CR61","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","volume":"13","author":"JN Vo","year":"2022","unstructured":"Vo JN, Wu Y-M, Mishler J, Hall S, Mannan R, Wang L, et al. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun. 2022;13(1):3750.","journal-title":"Nat Commun"},{"key":"5417_CR62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/PO.20.00360","volume":"5","author":"R Caeser","year":"2021","unstructured":"Caeser R, Walker I, Gao J, Shah N, Rasso-Barnett L, Anand S, et al. Acquired CARD11 mutation promotes BCR independence in Diffuse Large B Cell Lymphoma. JCO Precis Oncol. 2021;5:145\u201352.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"5417_CR63","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91\u2013101.","journal-title":"Cancer Cell"},{"key":"5417_CR64","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1182\/blood-2023-181974","volume":"142","author":"JS Walker","year":"2023","unstructured":"Walker JS, Wenzl K, Novak JP, Manske M, Serres M, Bock AM, et al. Truncating SPEN mutations highlight BN2-subtype DLBCL with aggressive biology and features of immune evasion. Blood. 2023;142:4140.","journal-title":"Blood"},{"issue":"5","key":"5417_CR65","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41419-018-0545-6","volume":"9","author":"J Guo","year":"2018","unstructured":"Guo J, Zhao Y, Fei C, Zhao S, Zheng Q, Su J, et al. Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells. Cell Death Dis. 2018;9(5):512.","journal-title":"Cell Death Dis"},{"issue":"45","key":"5417_CR66","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1038\/onc.2014.150","volume":"33","author":"TJ Pugh","year":"2014","unstructured":"Pugh TJ, Yu W, Yang J, Field AL, Ambrogio L, Carter SL, et al. Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences. Oncogene. 2014;33(45):5295\u2013302.","journal-title":"Oncogene"},{"issue":"10","key":"5417_CR67","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12032-014-0206-2","volume":"31","author":"H Zhao","year":"2014","unstructured":"Zhao H, Zhang L, Guo S, Yuan T, Xia B, Qu F, et al. Downregulated expression of Dicer1 predicts inferior survival in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab. Med Oncol. 2014;31(10):206.","journal-title":"Med Oncol"},{"issue":"1","key":"5417_CR68","doi-asserted-by":"publisher","first-page":"15899","DOI":"10.1038\/s41598-020-72946-z","volume":"10","author":"R Romero-Garc\u00eda","year":"2020","unstructured":"Romero-Garc\u00eda R, G\u00f3mez-Jaramillo L, Mateos RM, Jim\u00e9nez-G\u00f3mez G, Pedre\u00f1o-Horrillo N, Foncubierta E, et al. Differential epigenetic regulation between the alternative promoters, PRDM1\u03b1 and PRDM1\u03b2, of the tumour suppressor gene PRDM1 in human multiple myeloma cells. Sci Rep. 2020;10(1):15899\u201315899.","journal-title":"Sci Rep"},{"issue":"3","key":"5417_CR69","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/leu.2016.243","volume":"31","author":"Y Xia","year":"2017","unstructured":"Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, et al. Loss of PRDM1\/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia. 2017;31(3):625\u201336.","journal-title":"Leukemia"},{"issue":"4","key":"5417_CR70","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3960\/jslrt.21015","volume":"61","author":"D Ennishi","year":"2021","unstructured":"Ennishi D. The biology of the tumor microenvironment in DLBCL: targeting the \u201cdon\u2019t eat me\u201d signal. J Clin Exp Hematop. 2021;61(4):210\u20135.","journal-title":"J Clin Exp Hematop"},{"key":"5417_CR71","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ortiz A, Rodr\u00edguez-Garc\u00eda Y, Encinas J, Maroto-Mart\u00edn E, Castellano E, Teixid\u00f3 J, et al. The role of tumor microenvironment in multiple myeloma development and progression. Cancers (Basel). 2021;13(2).","DOI":"10.3390\/cancers13020217"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05417-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:02:57Z","timestamp":1789002177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05417-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5417"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05417-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Gerash University of Medical Sciences (Ethics Approval Code: IR.GERUMS.REC. 404000039). All procedures were conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants or their legal guardians where applicable. All procedures and tests were conducted following the acquisition of informed written consent from the patient, in accordance with ethical standards.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of the patient\u2019s clinical images and associated information was obtained from the patient.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1321"}}